Rewiring Antitumor Immunity: Targeting CLDN18.2 with Conditional 4-1BB Activation

Claudin 18.2 has emerged as a validated target in solid tumors, spurring next-generation therapies. Bispecific antibodies linking Claudin 18.2 to conditional 4-1BB activation offer a novel approach to enhance T-cell function. By confining costimulation to the tumor microenvironment, they aim to boost efficacy while limiting systemic toxicity. See related article by Ku et al., p. 4944.